Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Long-Term Safety
Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study
Posted inNeurology news

Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study

Posted by MedXY By MedXY 10/23/2025
This article reviews the long-term safety and efficacy of satralizumab in neuromyelitis optica spectrum disorder based on the SAkuraMoon extension trial.
Read More
Long-Term Safety of Antenatal Corticosteroids: Insights from the 50-Year Follow-Up of the Auckland Steroid Trial
Posted innews OB/GYN & Women's Health Specialties

Long-Term Safety of Antenatal Corticosteroids: Insights from the 50-Year Follow-Up of the Auckland Steroid Trial

Posted by MedXY By MedXY 08/11/2025
The 50-year follow-up study on the Auckland Steroid Trial provides reassurance about the intergenerational safety of antenatal corticosteroid exposure concerning body mass index and various health outcomes in the second generation.
Read More
  • Optimizing Post-Operative Outcomes: The Critical Impact of Specialist Cardiology Evaluation in Peri-operative Myocardial Infarction and Injury
  • IVUS Guidance Slashes 1-Year Target Vessel Failure in Complex Bifurcation PCI: Insights from DKCRUSH VIII
  • Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis
  • Optimizing the Synergy: Sequential vs. Concurrent Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer
  • Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in